Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

Inclusion Criteria:

• Histologically or cytologically documented locally advanced or metastatic solid tumormalignancy.
• Progressed or was intolerant to all available therapies known to confer clinicalbenefit appropriate for their tumor type for which the patient was eligible andwilling to receive.
• Adequate bone marrow, kidney and liver function
• Performance status of 0 or 1.
• Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade 1except for AEs not constituting a safety risk by Investigator judgement.

Exclusion Criteria:

• Prior treatment targeting LAIR1